Cargando…

The genetic and clinical characteristics and effects of Canakinumab on cryopyrin-associated periodic syndrome: a large pediatric cohort study from China

Cryopyrin-associated periodic syndrome (CAPS) comprises a group of disorders characterized by recurrent bouts of systemic inflammation related to overactivation of inflammasome. So far, neither large cases of the correlation between genotype and phenotype nor treatment strategies have been clearly s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shu, Zhou, Zhang, Yue, Han, Tongxin, Li, Yan, Piao, Yurong, Sun, Fei, Ma, Jin, Mo, Wenxiu, Sun, Jiapeng, Chan, Koon-Wing, Yang, Wanling, Lau, Yu-Lung, Mao, Huawei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551459/ https://www.ncbi.nlm.nih.gov/pubmed/37809096 http://dx.doi.org/10.3389/fimmu.2023.1267933

Ejemplares similares

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
por: Toker, Ori, et al.
Publicado: (2010)

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
por: Salugina, Svetlana O, et al.
Publicado: (2014)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
por: Caorsi, R, et al.
Publicado: (2011)

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age
por: Caorsi, Roberta, et al.
Publicado: (2013)

Live‐attenuated vaccines in a cryopyrin‐associated periodic syndrome patient receiving canakinumab treatment during infancy
por: Watanabe, Misa, et al.
Publicado: (2017)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study
por: Mulders-Manders, Catharina M., et al.
Publicado: (2018)

Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger
por: Brogan, Paul A., et al.
Publicado: (2019)

Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry
por: Walker, Ulrich A, et al.
Publicado: (2021)

Progressive osseous heteroplasia in a 5-year-old boy with a novel mutation in exon 2 of GNAS: a case presentation and literature review
por: Ma, Jing, et al.
Publicado: (2023)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
por: Bader-Meunier, B, et al.
Publicado: (2011)

Panniculitis with late onset enthesitis-related arthritis: a case report
por: Mo, Wenxiu, et al.
Publicado: (2023)

A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report
por: Hansmann, Sandra, et al.
Publicado: (2011)

Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD)
por: Li, Yan, et al.
Publicado: (2023)

Neurology of the Cryopyrin-Associated Periodic Feversyndrome
por: Parker, T, et al.
Publicado: (2015)

Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome
por: Elmi, Abdulkadir A., et al.
Publicado: (2019)

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2011)

Erythema nodosum in an adolescent patient with cryopyrin‐associated periodic syndrome
por: Chan, Linda, et al.
Publicado: (2018)

National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
por: Bibalo, C, et al.
Publicado: (2011)

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
por: Gillespie, Justin, et al.
Publicado: (2010)

Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System
por: Keddie, Stephen, et al.
Publicado: (2018)

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
por: Kümmerle-Deschner, J, et al.
Publicado: (2008)

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study
por: Koné-Paut, Isabelle, et al.
Publicado: (2011)

Cryopyrin-Associated Periodic Syndrome: An Update on Diagnosis and Treatment Response
por: Yu, Justin R., et al.
Publicado: (2010)

Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS)
por: Mamoudjy, Nafissa, et al.
Publicado: (2017)

The First Case Series of Cryopyrin-Associated Periodic Syndrome in Korea
por: Han, Jong Hee, et al.
Publicado: (2019)

Most Important Factors in Diagnosing Cryopyrin-Associated Periodic Syndrome
por: Lee, Soyoung, et al.
Publicado: (2021)

Interleukin-1β inhibitors for the treatment of cryopyrin-associated periodic syndrome
por: Dhimolea, Eugen
Publicado: (2011)

Unified Modeling of Familial Mediterranean Fever and Cryopyrin Associated Periodic Syndromes
por: Bozkurt, Yasemin, et al.
Publicado: (2015)

Unified modeling of Familial Mediterranean Fever and Cryopyrin Associated Periodic Syndromes
por: Gul, A, et al.
Publicado: (2015)

In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
por: Lachmann, Helen J., et al.
Publicado: (2009)

Evidence based recommendations for diagnosis and treatment of cryopyrin-associated periodic syndromes (CAPS)
por: Haar, Nienke Ter, et al.
Publicado: (2014)

Obvious optic disc swelling in a patient with cryopyrin-associated periodic syndrome
por: Kawai, Mariko, et al.
Publicado: (2013)

Cryopyrin‐associated periodic syndrome with inflammatory bowel disease: A case study
por: Raymond, Karen N, et al.
Publicado: (2021)

Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes
por: Bachove, Inessa, et al.
Publicado: (2014)

Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
por: Quartier, Pierre
Publicado: (2011)

Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes
por: Kullenberg, Torbjörn, et al.
Publicado: (2016)

Off-label use of canakinumab in pediatric rheumatology and rare diseases
por: Del Giudice, Emanuela, et al.
Publicado: (2022)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

PReS-FINAL-2234: Successful canakunimab treatment in uveitis secondary to cryopyrin-associated periodic syndrome
por: Kasapcopur, O, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_snbhd0okmt4aplsr9h78i778og